BeOne Medicines (ONC) Operating Expenses (2015 - 2026)

On a trailing twelve-month basis, BeOne Medicines' Operating Expenses was $4.53 billion through Jun 30, 2026, up 13.1% year-over-year; for FY2025, it came in at $4.23 billion, up 11.7% from FY2024.

• Operating Expenses has now increased for 11 consecutive years, with a five-year compound annual growth rate of 16.5% (FY2020 to FY2025).
• In earlier years, Operating Expenses was $3.78 billion in FY2024 (+15.1%), $3.29 billion in FY2023 (+12.6%), $2.92 billion in FY2022 (+19.1%) and $2.45 billion in FY2021 (+24.6%).
• The Q2 2026 figure marks the highest quarterly Operating Expenses in data going back to Q1 2015.
• Compared with a year earlier, Operating Expenses has increased for 11 straight quarters, with growth averaging 13.5% over the last eight quarters.
• The best year-over-year quarter for Operating Expenses over five years was Q4 2023 (growth of 62.3%); the worst was Q4 2022 (a decline of 9.4%).
• Per Business Quant data, ONC's Operating Expenses in the three quarters before Q2 2026 was $1.1 billion (Q1 2026), $1.17 billion (Q4 2025) and $1.05 billion (Q3 2025).